Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
McKesson
Colorcon
McKinsey
Baxter

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VITAMIN A PALMITATE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Vitamin A Palmitate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000116 Randomized Trial for Retinitis Pigmentosa Completed National Eye Institute (NEI) Phase 3 1996-05-01 The purpose of this trial is to determine whether a nutritional supplement in addition to vitamin A will slow the course of retinitis pigmentosa.
NCT00001972 PET Scan of Brain Metabolism in Relation to Age and Disease Completed National Institute of Neurological Disorders and Stroke (NINDS) N/A 1994-09-01 The main source of energy for the brain comes from a combination of oxygen and glucose (sugar). For brain cells to function normally they must receive a constant supply of these nutrients. As areas of the brain become more active blood flow into and out of these areas increase. In addition to oxygen and glucose, the brain uses chemical compounds known as phospholipids. These phospholipids make up the covering of nerve cells that assist in the transfer of information from cell to cell. Without phospholipids brain cell activity may become abnormal and cause problems in the nervous system. Certain diseases like Alzheimer's disease and brain tumors can affect blood flow to the brain and change the way the brain metabolizes phospholipids. In addition to diseases, changes in the brain occur with normal healthy aging. This study is designed to use PET scan to measure changes in blood flow and changes in phospholipid metabolism. Using this technique, researchers can improve their understanding of how certain diseases change the shape and function of the brain.
NCT00063596 Vitamin A Supplementation in Preterm Infants Unknown status Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) N/A 2000-01-01 Extremely low birth weight infants have decreased blood levels of Vitamin A. This Vitamin A deficiency may increase the risk of infections and chronic lung disease in these infants. This study will examine the effects of Vitamin A supplementation in premature babies born weighing less than 1500 grams (3.3 lbs).
NCT00065455 Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa Completed National Eye Institute (NEI) Phase 1 2003-07-01 Retinitis pigmentosa (RP) is a collective term for a group of inherited retinal dystrophies that are a major cause of irreversible blindness. RP of some type occurs in approximately 1 out of 3500 persons in the United States(1). Gene mutations are responsible for the majority of RP. To date, mutations have been identified in 30 different genes linked to RP(2). The visual prognosis of RP is poor, since the gradual but relentless visual field loss leads eventually to some degree of blindness(3). Although no effective treatment for RP has been identified, participants supplemented with a daily oral dose of 15,000 IU vitamin A palmitate have shown, on average, a slower rate of deterioration of retinal function when the intervention is continued over several years(4). The purpose of this research is to determine whether administration of high oral doses of vitamin A can acutely improve cone photoreceptor function in RP participants as measured by electroretinography (ERG). In this interventional, non-randomized, prospective, pilot study, 5 participants will receive a daily oral dose of 50,000 IU of vitamin A palmitate for 4 weeks, followed by a maintenance dose of 15,000 IU daily for the subsequent 2 weeks. The primary efficacy outcome is a relative percentage change in ERG response amplitude subsequent to vitamin A supplementation. A secondary efficacy outcome is a relative percentage change in implicit time from pre- to post- vitamin A supplementation, with improvement specified as a shorter response implicit time. Other secondary outcomes will be improvements in visual field (Humphery, 10-2; sum of thresholds). Safety outcomes include visual fields, ETDRS visual acuity, intraocular pressure, serum vitamin A level and liver function tests.
NCT00073320 Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2003-08-01 The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vitamin A Palmitate

Condition Name

Condition Name for Vitamin A Palmitate
Intervention Trials
Schizophrenia 48
Insulin Resistance 4
Type 2 Diabetes Mellitus 3
Retinitis Pigmentosa 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vitamin A Palmitate
Intervention Trials
Schizophrenia 50
Insulin Resistance 6
Diabetes Mellitus, Type 2 6
Diabetes Mellitus 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vitamin A Palmitate

Trials by Country

Trials by Country for Vitamin A Palmitate
Location Trials
United States 247
Korea, Republic of 16
Canada 13
Taiwan 11
Ukraine 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vitamin A Palmitate
Location Trials
California 20
Texas 19
Missouri 13
New York 13
Ohio 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vitamin A Palmitate

Clinical Trial Phase

Clinical Trial Phase for Vitamin A Palmitate
Clinical Trial Phase Trials
Phase 4 26
Phase 3 28
Phase 2/Phase 3 1
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vitamin A Palmitate
Clinical Trial Phase Trials
Completed 58
Recruiting 12
Not yet recruiting 10
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vitamin A Palmitate

Sponsor Name

Sponsor Name for Vitamin A Palmitate
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 11
Janssen Scientific Affairs, LLC 6
Janssen Research & Development, LLC 6
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vitamin A Palmitate
Sponsor Trials
Other 74
Industry 51
NIH 15
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKinsey
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.